$ACOR on NASDAQ
November 13, 2023
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
November 06, 2023
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
November 06, 2023
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
August 08, 2023
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
August 02, 2023
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
August 01, 2023
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
June 28, 2023
Tom Burns Elected to the Acorda Therapeutics Board of Directors
June 26, 2023
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
June 02, 2023
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
May 31, 2023
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
May 30, 2023
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
May 11, 2023
Acorda Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
May 08, 2023
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
May 04, 2023
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
April 24, 2023
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
April 03, 2023
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
March 27, 2023
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
March 09, 2023
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 07, 2023
ESTEVE Launches INBRIJA® in Spain
March 06, 2023
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
February 14, 2023
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
January 31, 2023
Acorda Therapeutics to Present at Sequire Biotechnology Conference
January 05, 2023
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
December 22, 2022
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
December 20, 2022
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
December 05, 2022
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
November 11, 2022
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
November 04, 2022
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
November 01, 2022
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
October 25, 2022
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
October 21, 2022
Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
October 19, 2022
ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
October 18, 2022
Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
October 16, 2022
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
October 10, 2022
Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders
September 08, 2022
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
August 19, 2022
Acorda Therapeutics Announces Resignation of Chief Operating Officer
August 04, 2022
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
July 28, 2022
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
March 09, 2022
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
January 04, 2022
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022
John Varian Joins Acorda Therapeutics Board of Directors
November 09, 2021
Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team
November 09, 2021
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
November 02, 2021
Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021
September 09, 2021
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
- No Recent Filings Found.
